Join us at booth C6347 at The Union World Conference on Lung Health and explore how we are actively committed to combatting Tuberculosis (TB) and supporting the responsible use of antibiotics to treat it.

In an exciting development for TB treatment and diagnostics, BD is preparing to help make Bedaquiline drug susceptibility testing more executable with the introduction of Bedaquiline antimicrobial reagent in lyophilized format (170 ug/vial)*. Bedaquiline, a drug recommended by the World Health Organization (WHO) for multi-drug resistant TB (MDR-TB) and other forms of drug-resistant TB¹, has seen limited susceptibility testing worldwide². The introduction of this antimicrobial reagent by BD aims to dramatically change this situation, potentially reducing the number of MDR-TB cases by enabling more accurate treatment.

Furthermore, BD has achieved a significant milestone with the World Health Organization (WHO) endorsing the BD MAX™ Molecular MDR-TB assay**. This recognition by WHO underscores the high diagnostic accuracy of the BD MAX™ MDR-TB assay and has led to its inclusion in the updated WHO guidelines for TB diagnostic testing. Notably, a study by David et al. found that the BD MAX™ MDR-TB assay outperformed other WHO-endorsed moderate-complexity automated NAATs for detecting MDR-TB, making it a favoured choice among operators³. These advancements in TB diagnostics are promising steps toward more effective TB treatment and control worldwide.

Together we can partner to elevate the standard of diagnostics in TB